Vira Therapeutics

Austria
Innsbruck, Tyrol, Austria, 6020

Company profile

Vira Therapeutics company profile

ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients.

Business identity

Phone number
+43512272061
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2015-06-24

Headquarters

Postal code
6020
Country code
AT
Continent
Europe

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
1
Total equity funding
$4M
Last funding
Series A / $4M / 2015-06-24
Last equity funding
Series A / $4M
Investors
3
Lead investors
2
Founders
1
Articles
7
Exited on
2018-09-13

Founders and investors

Founders

Dorothee Holm-von Laer

Lead investors

Boehringer Ingelheim Venture FundEMBL Ventures

Investors

austria Wirtschaftsservice (aws)Boehringer Ingelheim Venture FundEMBL Ventures